<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-129235" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>New Onset Refractory Status Epilepticus</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bhatia</surname>
            <given-names>Kunal</given-names>
          </name>
          <aff>University of Mississippi Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>De Jesus</surname>
            <given-names>Orlando</given-names>
          </name>
          <aff>University of Puerto Rico, Medical Sciences Campus, Neurosurgery Section</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kunal Bhatia declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Orlando De Jesus declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>23</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-129235.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>New-onset refractory status epilepticus (NORSE) is an uncommon clinical entity with a mortality rate of 16-27% in adults and significant long-term neurological sequelae. Approximately 50% of patients with NORSE have an unknown etiology despite an extensive workup. There is a lack of consensus regarding the best treatment options available for managing patients with NORSE. However, immediate cessation of seizure activity, early institution of continuous infusion of anesthetic agents, and immunotherapies can play an important role in reducing morbidity and mortality in NORSE. This activity reviews the evaluation and treatment options available and highlights the healthcare team's role in managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the etiology of new-onset refractory status epilepticus.</p></list-item><list-item><p>Explain the pathophysiology of new-onset refractory status epilepticus.</p></list-item><list-item><p>Outline the typical presentation of a patient with new-onset refractory status epilepticus.</p></list-item><list-item><p>Summarize the treatment considerations for patients with new-onset refractory status epilepticus.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=129235&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=129235">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-129235.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The International League Against Epilepsy (ILAE) defines status epilepticus (SE) as continuous clinical and/or electrographic seizure activity, or recurrent seizure activity without recovery to baseline, lasting for &#x02265; 5 mins.<xref ref-type="bibr" rid="article-129235.r1">[1]</xref> If the seizure activity continues despite treatment with adequate doses of an initial benzodiazepine and an acceptable second-line intravenous (IV) antiepileptic medication, the patient is considered to have progressed into refractory status epilepticus (RSE).<xref ref-type="bibr" rid="article-129235.r2">[2]</xref> Super refractory status epilepticus (SRSE) is defined as RSE that continues or recurs despite the use of IV anesthetic agents for &#x02265; 24 hours, including those cases that recur upon withdrawal or cessation of anesthetic agents.<xref ref-type="bibr" rid="article-129235.r3">[3]</xref> RSE is seen in approximately 9% to 43% of all SE cases, with a reported in-hospital mortality of 15% to 33%.<xref ref-type="bibr" rid="article-129235.r4">[4]</xref><xref ref-type="bibr" rid="article-129235.r5">[5]</xref> It has been observed that approximately 4% to 12% of patients with SE eventually progress to SRSE, with in-hospital mortality reported to be as high as 40% to 54%.<xref ref-type="bibr" rid="article-129235.r6">[6]</xref><xref ref-type="bibr" rid="article-129235.r7">[7]</xref><xref ref-type="bibr" rid="article-129235.r8">[8]</xref></p>
        <p>The term new-onset refractory status epilepticus (NORSE) was first used by Wilder-Smith et al. in 2005 to describe cases of SRSE with no associated past medical history of epilepsy and with no identifiable cause despite initial evaluation.<xref ref-type="bibr" rid="article-129235.r9">[9]</xref> In 2018 an international group of experts proposed a consensus definition of NORSE and related conditions to allow a more standardized terminology to improve patient management and clinical research. NORSE is defined as a &#x0201c;clinical presentation characterized by new onset of refractory status epilepticus, in a patient without active epilepsy or other preexisting relevant neurological disorder (acute strokes, brain masses, drug overdoses, etc.), and without a clear acute or active structural, toxic or metabolic cause.&#x0201d; A closely related condition, febrile infection-related epilepsy syndrome (FIRES), has been defined as a subset of NORSE, associated with a prior febrile infection, with fever starting between 2 weeks to 24 hours before the onset of RSE.<xref ref-type="bibr" rid="article-129235.r10">[10]</xref> In contrast, patients with NORSE may or may not be associated with fever before the start of RSE.</p>
      </sec>
      <sec id="article-129235.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>In a large retrospective review, consisting of 130 NORSE cases, an etiology was not identified in 52% of cases despite an extensive evaluation. These cases were termed as &#x0201c;cryptogenic NORSE&#x0201d; or &#x0201c;NORSE of unknown etiology.&#x0201d;<xref ref-type="bibr" rid="article-129235.r11">[11]</xref>&#x000a0;The most common etiologies included autoimmune and paraneoplastic encephalitis followed by infections.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Non-paraneoplastic autoimmune encephalitis</bold>&#x000a0;- The most frequently detected antibodies include anti-NMDA (N-methyl-D-aspartate) receptor, anti-VGKC (voltage-gated potassium complex), anti-LGI1, and less commonly anti-Caspr2. Other autoimmune antibodies that have been found in patients with NORSE include - Anti-GABA, Anti-glycine, Anti-GAD65, Anti-striational, and steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT).&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Paraneoplastic autoimmune encephalitis</bold>&#x000a0;- Anti NMDA receptor-associated encephalitis is the most common in this category. Young females are predominantly affected, and 50% of cases are associated with&#x000a0;germ cell tumors like ovarian teratoma. Other antibodies that have been identified include anti-Hu (small cell lung cancer, neuroblastoma), anti-CRMP5 (small cell lung cancer), anti-Ma2 (germ cell tumor of testis), anti-amphiphysin (breast cancer, small cell lung cancer), and anti-VGCC (small cell lung cancer, thymoma).&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Infections</bold>&#x000a0;- Herpes simplex virus type 1 (HSV-1) is the most common etiology identified in NORSE amongst infectious agents. Enterovirus, Epstein Barr virus (EBV), Varicella zoster virus (VZV), Cytomegalovirus (CMV), Bartonella henselae, Mycoplasma pneumoniae, and arboviruses (West Nile virus) have also been detected in patients with NORSE.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Some of the rare genetic conditions (POLG131), including mitochondrial defects, have also been associated with NORSE.<xref ref-type="bibr" rid="article-129235.r12">[12]</xref><xref ref-type="bibr" rid="article-129235.r13">[13]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-129235.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>NORSE and its subtype FIRES are relatively uncommon disorders, with most epidemiological data coming from case series. NORSE and FIRES have been reported in previously healthy young adults and school-aged children. However, adults &#x02265; 60 years have also been affected. It has been observed that females are affected more than males amongst adults, whereas boys are more frequently affected than girls in the pediatric population.<xref ref-type="bibr" rid="article-129235.r11">[11]</xref><xref ref-type="bibr" rid="article-129235.r14">[14]</xref></p>
        <p>Due to the lack of a clear definition of NORSE previously, it is possible that some of the cases were not diagnosed as NORSE. Hence, an accurate incidence of NORSE cannot be estimated reliably. However, it is estimated that NORSE represents approximately 20% of cases of RSE.<xref ref-type="bibr" rid="article-129235.r15">[15]</xref> Both NORSE and FIRES can occur in any age group with no ethnic or racial predilection.<xref ref-type="bibr" rid="article-129235.r14">[14]</xref></p>
      </sec>
      <sec id="article-129235.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>An immune-mediated inflammatory process has been postulated as the underlying pathophysiology in FIRES.<xref ref-type="bibr" rid="article-129235.r16">[16]</xref> In a study by Sakuma et al., the authors observed a marked overproduction of proinflammatory cytokines and chemokines in the cerebrospinal fluid (CSF) of children with FIRES, compared to CSF specimens from patients with other inflammatory neurological conditions.<xref ref-type="bibr" rid="article-129235.r17">[17]</xref> The upregulation of these inflammatory mediators could be secondary to activation of T cells, glial cells, and cells of the blood-brain barrier and perhaps have a role in epileptogenesis.<xref ref-type="bibr" rid="article-129235.r18">[18]</xref> However, additional mechanisms such as mitochondrial dysfunction or synaptic plasticity may also play a key role in seizure propagation.<xref ref-type="bibr" rid="article-129235.r15">[15]</xref></p>
        <p>Recently, a personal predisposition towards developing FIRES or NORSE has been hypothesized based on allelic variations in human leukocyte antigen subtypes and IL1 pathway.<xref ref-type="bibr" rid="article-129235.r19">[19]</xref><xref ref-type="bibr" rid="article-129235.r20">[20]</xref>&#x000a0;The fact that FIRES is a subtype of NORSE, a similar autoimmune inflammatory mechanism has been considered as the most likely mechanism in patients with NORSE. Further research studies are required to understand the exact underlying pathophysiological mechanism in patients with NORSE and FIRES.</p>
      </sec>
      <sec id="article-129235.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>NORSE and its subtype FIRES can develop in previously healthy adults or children and share some common clinical characteristics. Approximately 60% of patients with NORSE experience a prodromal illness, typically 1 to 14 days before the onset of seizure or SE.<xref ref-type="bibr" rid="article-129235.r11">[11]</xref> Prodromal symptoms may include confusion, fatigue, headache, mild febrile illness, behavioral changes, mild gastroenteritis, upper respiratory tract infection, and memory complaints.<xref ref-type="bibr" rid="article-129235.r11">[11]</xref><xref ref-type="bibr" rid="article-129235.r21">[21]</xref><xref ref-type="bibr" rid="article-129235.r22">[22]</xref>&#x000a0;Fever is absent in up to 1/3 cases of NORSE, but, by definition, it is universally present in FIRES.<xref ref-type="bibr" rid="article-129235.r11">[11]</xref>&#x000a0;There is complete cessation of fever in approximately 50% of patients before the first seizure episode.<xref ref-type="bibr" rid="article-129235.r14">[14]</xref></p>
        <p>At the onset, seizures are usually brief and isolated with a propensity to gradually increase in number within a few hours to days and eventually evolve into SE. The number of seizures can be up &#x02265; 100/day in children. Focal motor seizures are the most common seizure type seen, which may spread and generalize into bilateral tonic-clonic seizures. Other seizure types may include myoclonic seizures affecting the oro-facial muscles or focal seizures associated with impaired awareness. Seizures can last anywhere from a few days to weeks before progressing to SE.<xref ref-type="bibr" rid="article-129235.r9">[9]</xref><xref ref-type="bibr" rid="article-129235.r14">[14]</xref><xref ref-type="bibr" rid="article-129235.r23">[23]</xref><xref ref-type="bibr" rid="article-129235.r24">[24]</xref><xref ref-type="bibr" rid="article-129235.r25">[25]</xref>&#x000a0;</p>
        <p>Once the seizures evolve into SE, they remain refractory to the first and second-line treatment options, requiring admission to the intensive care unit (ICU) for further aggressive treatment options. Patients with unknown etiology or &#x0201c;cryptogenic NORSE&#x0201d; have been observed to have similar clinical features and disease course compared to patients with NORSE caused by autoimmune encephalitis but with a longer duration and severity of seizures associated with respiratory involvement requiring mechanical ventilation and worse outcomes.<xref ref-type="bibr" rid="article-129235.r11">[11]</xref><xref ref-type="bibr" rid="article-129235.r22">[22]</xref></p>
      </sec>
      <sec id="article-129235.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Patients who present with SE should undergo an initial laboratory workup, including a complete blood count, comprehensive metabolic profile, creatine kinase, C-reactive protein, erythrocyte sedimentation rate, calcium, magnesium, and phosphorus levels. Urine and blood toxicology screen (alcohol, amphetamine, cocaine, fentanyl, benzodiazepines, heavy metals, synthetic cannabinoids, ecstasy, and bath salts) should be sent on admission.<xref ref-type="bibr" rid="article-129235.r26">[26]</xref> For patients who progress to&#x000a0;RSE and the initial workup fails to elucidate an etiology, additional laboratory investigations should then be considered to focus on autoimmune and uncommon infectious etiologies.&#x000a0;</p>
        <p>
<bold>Laboratory</bold>
</p>
        <p>A lumbar puncture should be performed if no clear etiology can be found on initial testing. Routine CSF studies, including cell count, protein, glucose, lactate, markers of inflammation (oligoclonal bands and IgG index), gram stain, bacteria culture, and cytology should be sent. Additional CSF studies should include fungal stain and cultures for M. tuberculosis, polymerase chain reaction (PCR) for HSV-1/2, Epstein Barr virus (EBV), Varicella zoster virus (VZV), HIV-1/2, Chlamydia pneumoniae, Mycoplasma pneumoniae, and VDRL in selected cases when the etiology remains unknown.<xref ref-type="bibr" rid="article-129235.r26">[26]</xref> In approximately 2/3 of NORSE cases, mild CSF pleocytosis (&#x02264; 10 cells/&#x003bc;l) with elevated protein and normal glucose can be seen, with no significant difference in CSF findings between cryptogenic cases and cases with identifiable etiology.<xref ref-type="bibr" rid="article-129235.r11">[11]</xref>&#x000a0;HSV PCR has high sensitivity (98 %) and specificity (99 %) and is positive early in the course of HSV meningitis/encephalitis. However, HSV PCR can be negative when LP is performed less than 24 hours from the onset of neurological symptoms.</p>
        <p>Both CSF and serum should be tested for autoimmune anti-NMDA receptor, anti-VGKC (LGI1 and Caspr2), anti-AMPA, anti-GABA, and paraneoplastic antibodies (Anti-Hu, anti-CRMP5, anti-amphiphysin, anti-VGCC). An autoimmune panel (ANA, ANCA, Anti Ro, Anti La, Antithyroid antibodies, anti-Scl-70) should be sent for further testing. Viral serologies, most commonly HSV-1/2, VZV, EBV, enterovirus, and HIV-1/2, should be ordered in all patients with NORSE.<xref ref-type="bibr" rid="article-129235.r26">[26]</xref>&#x000a0;For immunocompromised patients, serologies should be sent for IgG Cryptococcus species, IgM and IgG Histoplasma capsulatum, and IgG Toxoplasma gondii. Stool specimens should be investigated for adenovirus and enterovirus. A scrotal ultrasound, pelvis magnetic resonance imaging (MRI), chest/abdomen/pelvis computed tomographic (CT) scan, and whole-body PET-CT are recommended to screen for an underlying malignancy in patients with suspicion for a paraneoplastic process.&#x000a0;</p>
        <p>
<bold>Neuroimaging</bold>
</p>
        <p>All patients with NORSE and FIRES should have a brain MRI with contrast, including&#x000a0;venography and angiography, to evaluate structural or focal abnormalities. In approximately 60% of NORSE cases, symmetrical or asymmetrical abnormalities can be seen on the brain MRI.<xref ref-type="bibr" rid="article-129235.r11">[11]</xref> The most common findings observed include hyperintensity on T2/FLAIR&#x000a0;sequences within the limbic and neocortical structures, often bilaterally. Other brain regions like the claustrum, basal ganglia/thalami, and peri-insular cortex can show abnormal T2/FLAIR hyperintensity.<xref ref-type="bibr" rid="article-129235.r27">[27]</xref><xref ref-type="bibr" rid="article-129235.r28">[28]</xref></p>
        <p>
<bold>Electroencephalography (EEG)</bold>
</p>
        <p>All patients should have continuous EEG monitoring (cEEG) to assess seizure type and frequency, rule out non-convulsive status epilepticus (NCSE) and monitor therapy response. The neurocritical care society guidelines recommend initiating cEEG in all patients within 1 hour of onset of SE.<xref ref-type="bibr" rid="article-129235.r2">[2]</xref> EEG may demonstrate periodic or epileptiform discharges, which are most commonly lateralized or focal, generalized periodic discharges, and multifocal discharges.<xref ref-type="bibr" rid="article-129235.r14">[14]</xref><xref ref-type="bibr" rid="article-129235.r27">[27]</xref>&#x000a0;</p>
        <p>The most common seizure noted in one series was focal onset followed by bilateral independent, generalized, and&#x000a0;multifocal seizures. Seizures are brief and infrequent at the onset, associated with focal fast beta activity with a gradual evolution to SE characterized by rhythmic spike and wave complexes or beta-delta activity.<xref ref-type="bibr" rid="article-129235.r29">[29]</xref>&#x000a0;Some EEG patterns may provide clues to a specific diagnosis in a few cases. In&#x000a0;1/3 of the anti-NMDA receptor encephalitis cases, EEG monitoring may show a specific extreme-delta brush pattern characterized by beta bursts overriding delta waves.<xref ref-type="bibr" rid="article-129235.r30">[30]</xref></p>
      </sec>
      <sec id="article-129235.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Status epilepticus is a neurological emergency that requires the immediate cessation of seizure activity to prevent permanent neurological injury. Initial management should be following the currently available guidelines.<xref ref-type="bibr" rid="article-129235.r2">[2]</xref><xref ref-type="bibr" rid="article-129235.r31">[31]</xref><xref ref-type="bibr" rid="article-129235.r32">[32]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Patients should be stabilized first with regards to their cardiocirculatory function.</p>
          </list-item>
          <list-item>
            <p>Airway patency and safety should be ensured. Supplemental O2 through a nasal cannula or other non-invasive methods should be considered to ensure oxygenation before advancing to intubation and mechanical ventilation.</p>
          </list-item>
          <list-item>
            <p>Rapid sequence intubation should be performed in patients with impaired oxygenation or ventilation despite conservative measures.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Intravenous (IV) benzodiazepines are the agents of choice for aborting seizures emergently. The use of benzodiazepines in the prehospital setting has been shown to terminate seizures in 43% to 59% cases with SE, en-route to the hospital, with less need for respiratory support on arrival to the emergency department and need for ICU subsequently. Intramuscular (IM) midazolam has been observed to be superior and more efficacious than IV lorazepam in patients without IV access.<xref ref-type="bibr" rid="article-129235.r33">[33]</xref> However, IM midazolam, IV lorazepam, IV diazepam, and IV phenobarbital have been recommended as initial drugs of choice for aborting seizures lasting at least 5 minutes, with similar efficacy.<xref ref-type="bibr" rid="article-129235.r31">[31]</xref></p>
          </list-item>
          <list-item>
            <p>IV acyclovir should be started early during the course of illness in patients with suspicion for HSV encephalitis (acute febrile encephalopathy, new-onset seizures, asymmetric medial temporal lobe involvement, and lymphocytic pleocytosis with RBCs on CSF analysis), pending HSV-PCR results in CSF. It&#x000a0;has been shown to reduce mortality and morbidity when started early in the course of illness.</p>
          </list-item>
          <list-item>
            <p>In patients with benzodiazepine refractory SE, a second-line antiepileptic agent should be attempted immediately&#x000a0;at appropriate doses. In a randomized control trial, IV levetiracetam, IV fosphenytoin, and IV sodium valproate were shown to have similar safety and efficacy in established SE patients.<xref ref-type="bibr" rid="article-129235.r34">[34]</xref>&#x000a0;The effectiveness of each subsequent antiepileptic added in aborting status epilepticus decreases after initiating the first antiepileptic agent</p>
          </list-item>
          <list-item>
            <p>If seizures continue despite treatment with a second-line agent, another anti-epileptic agent should be used before progressing to IV anesthetic agents. IV phenytoin/fosphenytoin, phenobarbital, valproate, levetiracetam, and lacosamide; have been noted to be effective in the treatment of established SE with no preference over each other.<xref ref-type="bibr" rid="article-129235.r32">[32]</xref>&#x000a0;Hence one of these agents, either as single or in combination, can be used for treatment.</p>
          </list-item>
        </list>
        <p>By definition, patients who fail to respond to first and second-line therapies progress to refractory SE and require treatment with continuous IV anesthetic agents to achieve seizure control.</p>
        <list list-type="bullet">
          <list-item>
            <p>Current guidelines recommend using continuous IV infusion of anesthetic agents for seizure suppression or burst suppression coma for 24-48 hours before attempting to wean.<xref ref-type="bibr" rid="article-129235.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>Midazolam:&#x000a0;Load with 0.2 mg/kg IV followed by continuous infusion at 0.05&#x000a0;to 2 mg/kg/hr.</p>
          </list-item>
          <list-item>
            <p>Propofol:&#x000a0;2 mg/kg IV bolus followed by maintenance infusion&#x000a0;at 20&#x000a0;to 250 mcg/kg/min.</p>
          </list-item>
          <list-item>
            <p>Pentobarbital: 5 mg/kg IV bolus, continuous infusion at 1&#x000a0;to 10 mg/kg/hr.</p>
          </list-item>
          <list-item>
            <p>Ketamine: Load with 0.5-4 mg/kg followed by maintenance infusion at 0.3&#x000a0;to 5 mg/kg/hr.</p>
          </list-item>
          <list-item>
            <p>IV midazolam and propofol are preferred over longer-acting agents like pentobarbital as long-acting agents are associated with a prolonged need for mechanical ventilation and cardiovascular complications.<xref ref-type="bibr" rid="article-129235.r35">[35]</xref><xref ref-type="bibr" rid="article-129235.r36">[36]</xref>&#x000a0;However, higher doses and prolonged treatment of propofol have been associated with propofol infusion syndrome leading to higher mortality and complications than midazolam and ketamine.&#x000a0;</p>
          </list-item>
        </list>
        <p>Patients with NORSE (or FIRES) often have a poor response to antiepileptic medications, and continuous IV anesthetic agents should be started without further delay, given the disease process's refractory nature. Multiple anesthetic agents are required in approximately 1/3 of patients with NORSE to achieve seizure suppression, and often for prolonged periods.<xref ref-type="bibr" rid="article-129235.r11">[11]</xref><xref ref-type="bibr" rid="article-129235.r16">[16]</xref>&#x000a0;Since no specific therapy exists for patients with NORSE/FIRES, experts recommend using immunotherapies as soon as possible since nearly half of the cases are associated with an autoimmune/paraneoplastic etiology.<xref ref-type="bibr" rid="article-129235.r15">[15]</xref><xref ref-type="bibr" rid="article-129235.r37">[37]</xref>&#x000a0;First-line immunotherapy agents include steroids, IV immunoglobulins, and plasmapheresis. Second-line options include tacrolimus, rituximab, cyclophosphamide, and anakinra. Immunotherapy has been shown to improve outcomes and control seizures more effectively in adults as compared to children.<xref ref-type="bibr" rid="article-129235.r22">[22]</xref><xref ref-type="bibr" rid="article-129235.r38">[38]</xref>&#x000a0;There are currently no randomized controlled trials or prospective studies to guide immunotherapy in such patients, and recommendations are mostly based on expert opinion and experience from case series.</p>
        <list list-type="bullet">
          <list-item>
            <p>Once the initial workup fails to elucidate a cause for RSE, and there is a high suspicion for NORSE, IV methylprednisolone should be started ideally within the first week at a dose of 1 gm/day for 3&#x000a0;to 5 days.</p>
          </list-item>
          <list-item>
            <p>Alternatively, other first-line treatment options (IV immunoglobulin 0.4 gm/day for 3&#x000a0;to 5 days or plasmapheresis for 3&#x000a0;to 5 sessions on alternate days) can be used depending on patient characteristics and clinical context.<xref ref-type="bibr" rid="article-129235.r15">[15]</xref><xref ref-type="bibr" rid="article-129235.r39">[39]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>If there is no response to first-line therapies, i.e., failure to wean anesthetic agents due to high risk of seizure recurrence or prolonged RSE, the following second-line immunotherapies can then be considered: IV rituximab 375&#x000a0;mg/m^2 weekly for four doses, or IV cyclophosphamide 500-1000 mg/m^2 monthly for 3&#x000a0;to 6 months.</p>
          </list-item>
          <list-item>
            <p>Anakinra, a recombinant version of the human Interleukin-1 receptor antagonist, has been observed to reduce the seizure frequency and achieve remission in two case reports.<xref ref-type="bibr" rid="article-129235.r40">[40]</xref><xref ref-type="bibr" rid="article-129235.r41">[41]</xref></p>
          </list-item>
          <list-item>
            <p>Other therapeutic options (hypothermia, cannabidiol, ketogenic diet), although less studied, have also been attempted in NORSE patients with mixed results and need to be validated.<xref ref-type="bibr" rid="article-129235.r42">[42]</xref><xref ref-type="bibr" rid="article-129235.r43">[43]</xref><xref ref-type="bibr" rid="article-129235.r44">[44]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-129235.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>In most of the cases of NORSE, an etiology remains unknown despite an extensive workup. However, autoimmune/paraneoplastic encephalitis remains the most common identifiable etiology in NORSE.<xref ref-type="bibr" rid="article-129235.r11">[11]</xref><xref ref-type="bibr" rid="article-129235.r45">[45]</xref>&#x000a0;Therefore, a detailed history and clinical examination should be sought as certain clinical features can point towards a specific underlying etiology leading to early immunotherapy during the acute phase, ultimately influencing outcomes and disability.</p>
        <list list-type="bullet">
          <list-item>
            <p>Anti-NMDA encephalitis is the most common autoimmune encephalitis and should be ruled out early. It usually starts as a febrile illness in young adults, common in females.<xref ref-type="bibr" rid="article-129235.r46">[46]</xref> This is soon followed by psychiatric disturbances like hallucinations (behavioral changes in children), sleep disturbances, hyperactivity, memory complaints, epileptic seizures, oro-lingual dyskinesias, and autonomic failure.<xref ref-type="bibr" rid="article-129235.r47">[47]</xref>&#x000a0;As compared to anti-NMDA encephalitis, patients with cryptogenic NORSE are more frequently associated with early onset of SE, prolonged disease course, absence of behavioral symptoms, ventilator dependence, and worse outcomes.<xref ref-type="bibr" rid="article-129235.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>Encephalitis with anti-VGKC complex antibodies (LGI1 or, more rarely, Caspr2) can present with limbic encephalitis (cognitive impairment, confusion, behavioral disturbances, sleep disturbances, and seizures) and abnormalities in serum sodium levels associated with the syndrome of inappropriate antidiuretic hormone secretion.<xref ref-type="bibr" rid="article-129235.r48">[48]</xref> Facio-brachial dystonic seizures can occur in patients with anti-LGI1 encephalitis and is a pathognomonic feature of the disease.<xref ref-type="bibr" rid="article-129235.r49">[49]</xref></p>
          </list-item>
          <list-item>
            <p>Amongst infectious causes, patients should be screened for uncommon infections as early as possible. HSV-1 infection can present with an acute illness consisting of fever, alteration in mentation, behavioral changes, multiple seizures (though uncommon to progress to RSE), focal neurological deficits (hemiparesis, ataxia, aphasia), without or without dermatomal rashes. Whereas lower motor neuron type weakness with rash and prodromal febrile illness can suggest an underlying enterovirus related infection.<xref ref-type="bibr" rid="article-129235.r11">[11]</xref><xref ref-type="bibr" rid="article-129235.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Systemic reversible causes like toxic-metabolic disturbances (heavy metals including lead, aluminum arsenic, mercury) and drug toxicity should be considered in the differential and evaluated appropriately.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-129235.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>NORSE (and FIRES in children) is an uncommon neurological condition associated with significant long-term morbidity and mortality. Most patients remain unresponsive to multiple anesthetic agents and evolve into SRSE. A 12% mortality rate has been seen in children and 16% to 27% in adults.<xref ref-type="bibr" rid="article-129235.r11">[11]</xref><xref ref-type="bibr" rid="article-129235.r14">[14]</xref><xref ref-type="bibr" rid="article-129235.r50">[50]</xref><xref ref-type="bibr" rid="article-129235.r51">[51]</xref>&#x000a0;</p>
        <p>Most of the survivors eventually develop multidrug-resistant epilepsy on long-term follow-up and significant cognitive and functional impairment. Prolonged ICU stay, medical complications, duration of barbiturate induced coma, and use of multiple anesthetic agents have been associated with worse outcomes both in children and adults.<xref ref-type="bibr" rid="article-129235.r11">[11]</xref><xref ref-type="bibr" rid="article-129235.r13">[13]</xref><xref ref-type="bibr" rid="article-129235.r14">[14]</xref><xref ref-type="bibr" rid="article-129235.r25">[25]</xref><xref ref-type="bibr" rid="article-129235.r52">[52]</xref></p>
      </sec>
      <sec id="article-129235.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Patients with NORSE often require multiple IV anesthetic agents for prolonged periods to achieve burst suppression coma. Inadvertently, this is often associated with greater risk of complications including cardiovascular (hypotension requiring the use of vasopressors, cardiac arrhythmias), gastrointestinal (liver dysfunction, ileus, gastric ulcers), infectious (pneumonia, urinary tract infection), hematological (anemia, thrombocytopenia, pulmonary embolism), electrolyte abnormalities (hypo or hypernatremia, hypophosphatemia, severe acidosis), and worse outcomes. The severity and risk of complications have been associated with a prolonged RSE duration and the need for multiple IV anesthetic agents.<xref ref-type="bibr" rid="article-129235.r11">[11]</xref></p>
      </sec>
      <sec id="article-129235.s12" sec-type="Consultations">
        <title>Consultations</title>
        <p>The following personnel should be consulted:</p>
        <list list-type="bullet">
          <list-item>
            <p>Neurologist</p>
          </list-item>
          <list-item>
            <p>Anesthesiologist</p>
          </list-item>
          <list-item>
            <p>Intensivist</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-129235.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>NORSE is a distinct clinical disorder with significant mortality and long-term morbidity. Existing evidence regarding the etiology, diagnostic workup, and treatment options is based on expert opinion and retrospective case series. Support should be offered to family members to provide education regarding possible neurological sequelae among NORSE survivors, including refractory epilepsy, functional and cognitive impairments.</p>
        <p>General awareness about the nature of the disease and treatment options available should be promoted amongst medical professionals by organizing meetings at both the institutional and national levels. NORSE is not a well recognized clinical entity amongst general neurologists or medical intensive care physicians, except in specialized tertiary level academic health institutions. Hence, improving professional education will result in early recognition and management of the disease, improving patient outcomes.</p>
      </sec>
      <sec id="article-129235.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>NORSE is relatively an uncommon clinical entity with no clear etiology in the majority of the cases. It is associated with significant mortality and long-term neurological sequelae, requiring a multidisciplinary approach for management. Although no prospective long-term studies are comparing the efficacy of different treatment options in NORSE, physicians should recognize such patients and initiate treatment early during the disease course to improve patient outcomes.</p>
        <p>Physicians and other health care team members, including nurses and pharmacists, should focus on the early institution of treatment, including the use of aggressive immunotherapies to reduce morbidity and mortality. Clear communication with an emphasis on discussing the uncertain nature of the diagnosis, treatment options available, and possible outcomes; should be maintained with the patient&#x02019;s family throughout the course of the disease. Palliative care services can be consulted early during the hospital course to offer support to the family members and facilitate care discussion goals should the need arise. They can play an essential role in building a strong relationship between the patient&#x02019;s family and the health care teams. Physicians should encourage families to participate in the national registry for NORSE patients (www.norseinstitute.org/norse-registry-2) to promote clinical research with an aim to understand possible causes of NORSE, identify best treatment options and hence improve patient outcomes.</p>
        <p>Overall, an interprofessional healthcare team approach to managing NORSE will yield the best patient outcomes. This team is comprised of clinicians, specialists, nursing staff, and pharmacists, working collaboratively with open communication lines to achieve the best possible care standard. [Level 5]</p>
      </sec>
      <sec id="article-129235.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=129235&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=129235">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/neurology/new-onset-refractory-status-epilepticus/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=129235">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/129235/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=129235">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-129235.s16">
        <title>References</title>
        <ref id="article-129235.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trinka</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cock</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hesdorffer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rossetti</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Scheffer</surname>
                <given-names>IE</given-names>
              </name>
              <name>
                <surname>Shinnar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shorvon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lowenstein</surname>
                <given-names>DH</given-names>
              </name>
            </person-group>
            <article-title>A definition and classification of status epilepticus--Report of the ILAE Task Force on Classification of Status Epilepticus.</article-title>
            <source>Epilepsia</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>56</volume>
            <issue>10</issue>
            <fpage>1515</fpage>
            <page-range>1515-23</page-range>
            <pub-id pub-id-type="pmid">26336950</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brophy</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Claassen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Alldredge</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bleck</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Glauser</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Laroche</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Riviello</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Shutter</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sperling</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Treiman</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Vespa</surname>
                <given-names>PM</given-names>
              </name>
              <collab>Neurocritical Care Society Status Epilepticus Guideline Writing Committee</collab>
            </person-group>
            <article-title>Guidelines for the evaluation and management of status epilepticus.</article-title>
            <source>Neurocrit Care</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-23</page-range>
            <pub-id pub-id-type="pmid">22528274</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shorvon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ferlisi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol.</article-title>
            <source>Brain</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>134</volume>
            <issue>Pt 10</issue>
            <fpage>2802</fpage>
            <page-range>2802-18</page-range>
            <pub-id pub-id-type="pmid">21914716</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rossetti</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Lowenstein</surname>
                <given-names>DH</given-names>
              </name>
            </person-group>
            <article-title>Management of refractory status epilepticus in adults: still more questions than answers.</article-title>
            <source>Lancet Neurol</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>10</volume>
            <issue>10</issue>
            <fpage>922</fpage>
            <page-range>922-30</page-range>
            <pub-id pub-id-type="pmid">21939901</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mayer</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Claassen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lokin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mendelsohn</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dennis</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Fitzsimmons</surname>
                <given-names>BF</given-names>
              </name>
            </person-group>
            <article-title>Refractory status epilepticus: frequency, risk factors, and impact on outcome.</article-title>
            <source>Arch Neurol</source>
            <year>2002</year>
            <month>Feb</month>
            <volume>59</volume>
            <issue>2</issue>
            <fpage>205</fpage>
            <page-range>205-10</page-range>
            <pub-id pub-id-type="pmid">11843690</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strzelczyk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ansorge</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hapfelmeier</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bonthapally</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Erder</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Rosenow</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Costs, length of stay, and mortality of super-refractory status epilepticus: A population-based study from Germany.</article-title>
            <source>Epilepsia</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>58</volume>
            <issue>9</issue>
            <fpage>1533</fpage>
            <page-range>1533-1541</page-range>
            <pub-id pub-id-type="pmid">28681418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Delaj</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Novy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ryvlin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Marchi</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Rossetti</surname>
                <given-names>AO</given-names>
              </name>
            </person-group>
            <article-title>Refractory and super-refractory status epilepticus in adults: a 9-year cohort study.</article-title>
            <source>Acta Neurol Scand</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>135</volume>
            <issue>1</issue>
            <fpage>92</fpage>
            <page-range>92-99</page-range>
            <pub-id pub-id-type="pmid">27080243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferlisi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shorvon</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy.</article-title>
            <source>Brain</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>135</volume>
            <issue>Pt 8</issue>
            <fpage>2314</fpage>
            <page-range>2314-28</page-range>
            <pub-id pub-id-type="pmid">22577217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilder-Smith</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Teoh</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Ong</surname>
                <given-names>BK</given-names>
              </name>
            </person-group>
            <article-title>The NORSE (new-onset refractory status epilepticus) syndrome: defining a disease entity.</article-title>
            <source>Ann Acad Med Singap</source>
            <year>2005</year>
            <month>Aug</month>
            <volume>34</volume>
            <issue>7</issue>
            <fpage>417</fpage>
            <page-range>417-20</page-range>
            <pub-id pub-id-type="pmid">16123813</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hirsch</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Gaspard</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>van Baalen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nabbout</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Demeret</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Loddenkemper</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Navarro</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Specchio</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lagae</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rossetti</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Hocker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gofton</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Abend</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Gilmore</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Khosravani</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rosenow</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Trinka</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions.</article-title>
            <source>Epilepsia</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>59</volume>
            <issue>4</issue>
            <fpage>739</fpage>
            <page-range>739-744</page-range>
            <pub-id pub-id-type="pmid">29399791</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gaspard</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Foreman</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Alvarez</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Cabrera Kang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Probasco</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Jongeling</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Meyers</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Espinera</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Haas</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Schmitt</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Gerard</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Gofton</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Legros</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Szaflarski</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Westover</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>LaRoche</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Hirsch</surname>
                <given-names>LJ</given-names>
              </name>
              <collab>Critical Care EEG Monitoring Research Consortium (CCEMRC)</collab>
            </person-group>
            <article-title>New-onset refractory status epilepticus: Etiology, clinical features, and outcome.</article-title>
            <source>Neurology</source>
            <year>2015</year>
            <month>Nov</month>
            <day>03</day>
            <volume>85</volume>
            <issue>18</issue>
            <fpage>1604</fpage>
            <page-range>1604-13</page-range>
            <pub-id pub-id-type="pmid">26296517</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rahman</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Mitochondrial diseases and status epilepticus.</article-title>
            <source>Epilepsia</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>59 Suppl 2</volume>
            <fpage>70</fpage>
            <page-range>70-77</page-range>
            <pub-id pub-id-type="pmid">30159903</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Husari</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Labiner</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Said</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title>New-Onset Refractory Status Epilepticus in Children: Etiologies, Treatments, and Outcomes.</article-title>
            <source>Pediatr Crit Care Med</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>59</fpage>
            <page-range>59-66</page-range>
            <pub-id pub-id-type="pmid">31568262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kramer</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Chi</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Specchio</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sahin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nabbout</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kluger</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>van Baalen</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Febrile infection-related epilepsy syndrome (FIRES): pathogenesis, treatment, and outcome: a multicenter study on 77 children.</article-title>
            <source>Epilepsia</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>52</volume>
            <issue>11</issue>
            <fpage>1956</fpage>
            <page-range>1956-65</page-range>
            <pub-id pub-id-type="pmid">21883180</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gaspard</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hirsch</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Sculier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Loddenkemper</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>van Baalen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lancrenon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Emmery</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Specchio</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Farias-Moeller</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nabbout</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES): State of the art and perspectives.</article-title>
            <source>Epilepsia</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>59</volume>
            <issue>4</issue>
            <fpage>745</fpage>
            <page-range>745-752</page-range>
            <pub-id pub-id-type="pmid">29476535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Baalen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vezzani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>H&#x000e4;usler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kluger</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Febrile Infection-Related Epilepsy Syndrome: Clinical Review and Hypotheses of Epileptogenesis.</article-title>
            <source>Neuropediatrics</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>48</volume>
            <issue>1</issue>
            <fpage>5</fpage>
            <page-range>5-18</page-range>
            <pub-id pub-id-type="pmid">27919115</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sakuma</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tanuma</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kuki</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shiomi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Intrathecal overproduction of proinflammatory cytokines and chemokines in febrile infection-related refractory status epilepticus.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>86</volume>
            <issue>7</issue>
            <fpage>820</fpage>
            <page-range>820-2</page-range>
            <pub-id pub-id-type="pmid">25398790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miskin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hasbani</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Status epilepticus: immunologic and inflammatory mechanisms.</article-title>
            <source>Semin Pediatr Neurol</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>21</volume>
            <issue>3</issue>
            <fpage>221</fpage>
            <page-range>221-5</page-range>
            <pub-id pub-id-type="pmid">25510944</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saitoh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ohmori</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Horino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ohmura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kumakura</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Takei</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hirabayashi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kajimoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Uchida</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yamazaki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shiihara</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kumagai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kasai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Terashima</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kubota</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mizuguchi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cytokine-related and sodium channel polymorphism as candidate predisposing factors for childhood encephalopathy FIRES/AERRPS.</article-title>
            <source>J Neurol Sci</source>
            <year>2016</year>
            <month>Sep</month>
            <day>15</day>
            <volume>368</volume>
            <fpage>272</fpage>
            <page-range>272-6</page-range>
            <pub-id pub-id-type="pmid">27538648</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gotkine</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kennedy</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Steiner</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Post infectious CNS disorders: towards a unified approach.</article-title>
            <source>J Neurol</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>257</volume>
            <issue>12</issue>
            <fpage>1963</fpage>
            <page-range>1963-9</page-range>
            <pub-id pub-id-type="pmid">20857134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>K&#x000f6;rtvelyessy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lerche</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>FIRES and NORSE are distinct entities.</article-title>
            <source>Epilepsia</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>53</volume>
            <issue>7</issue>
            <fpage>1276</fpage>
            <pub-id pub-id-type="pmid">22759241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iizuka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kanazawa</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kaneko</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tominaga</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nonoda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hara</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Onozawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Asari</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hata</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kaneko</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yoshida</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sugiura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ugawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tomita</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kosakai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kaneko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ishima</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kitamura</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nishiyama</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Cryptogenic NORSE: Its distinctive clinical features and response to immunotherapy.</article-title>
            <source>Neurol Neuroimmunol Neuroinflamm</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>4</volume>
            <issue>6</issue>
            <fpage>e396</fpage>
            <pub-id pub-id-type="pmid">28959704</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baxter</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Clarke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cross</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Harding</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hicks</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Livingston</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Surtees</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Idiopathic catastrophic epileptic encephalopathy presenting with acute onset intractable status.</article-title>
            <source>Seizure</source>
            <year>2003</year>
            <month>Sep</month>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>379</fpage>
            <page-range>379-87</page-range>
            <pub-id pub-id-type="pmid">12915084</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nabbout</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>FIRES and IHHE: Delineation of the syndromes.</article-title>
            <source>Epilepsia</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>54 Suppl 6</volume>
            <fpage>54</fpage>
            <page-range>54-6</page-range>
            <pub-id pub-id-type="pmid">24001074</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Howell</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Katanyuwong</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mackay</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Scheffer</surname>
                <given-names>IE</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Berkovic</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Harvey</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Long-term follow-up of febrile infection-related epilepsy syndrome.</article-title>
            <source>Epilepsia</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>53</volume>
            <issue>1</issue>
            <fpage>101</fpage>
            <page-range>101-10</page-range>
            <pub-id pub-id-type="pmid">22191582</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sculier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gaspard</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>New onset refractory status epilepticus (NORSE).</article-title>
            <source>Seizure</source>
            <year>2019</year>
            <month>May</month>
            <volume>68</volume>
            <fpage>72</fpage>
            <page-range>72-78</page-range>
            <pub-id pub-id-type="pmid">30482654</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mikaeloff</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jambaqu&#x000e9;</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hertz-Pannier</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zamfirescu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Adamsbaum</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Plouin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dulac</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Chiron</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Devastating epileptic encephalopathy in school-aged children (DESC): a pseudo encephalitis.</article-title>
            <source>Epilepsy Res</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>69</volume>
            <issue>1</issue>
            <fpage>67</fpage>
            <page-range>67-79</page-range>
            <pub-id pub-id-type="pmid">16469483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caraballo</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Reyes</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Avaria</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Buompadre</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fortini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cersosimo</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Febrile infection-related epilepsy syndrome: a study of 12 patients.</article-title>
            <source>Seizure</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>22</volume>
            <issue>7</issue>
            <fpage>553</fpage>
            <page-range>553-9</page-range>
            <pub-id pub-id-type="pmid">23643626</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farias-Moeller</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bartolini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Staso</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schreiber</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Carpenter</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Early ictal and interictal patterns in FIRES: The sparks before the blaze.</article-title>
            <source>Epilepsia</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>58</volume>
            <issue>8</issue>
            <fpage>1340</fpage>
            <page-range>1340-1348</page-range>
            <pub-id pub-id-type="pmid">28555777</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Capua</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Ptacek</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Garc&#x000ed;a</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Abarrategui</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Porta-Etessam</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Morales</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Extreme delta brush in a patient with anti-NMDAR encephalitis.</article-title>
            <source>Epileptic Disord</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>461</fpage>
            <page-range>461-4</page-range>
            <pub-id pub-id-type="pmid">24317133</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glauser</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shinnar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gloss</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Alldredge</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Arya</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bainbridge</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bare</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bleck</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dodson</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Garrity</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jagoda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lowenstein</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pellock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Riviello</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sloan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Treiman</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society.</article-title>
            <source>Epilepsy Curr</source>
            <year>2016</year>
            <season>Jan-Feb</season>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>48</fpage>
            <page-range>48-61</page-range>
            <pub-id pub-id-type="pmid">26900382</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Minicucci</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ferlisi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brigo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mecarelli</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Meletti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aguglia</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Michelucci</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mastrangelo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Specchio</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sartori</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tinuper</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Management of status epilepticus in adults. Position paper of the Italian League against Epilepsy.</article-title>
            <source>Epilepsy Behav</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>102</volume>
            <fpage>106675</fpage>
            <pub-id pub-id-type="pmid">31766004</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silbergleit</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lowenstein</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Durkalski</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Conwit</surname>
                <given-names>R</given-names>
              </name>
              <collab>Neurological Emergency Treatment Trials (NETT) Investigators</collab>
            </person-group>
            <article-title>RAMPART (Rapid Anticonvulsant Medication Prior to Arrival Trial): a double-blind randomized clinical trial of the efficacy of intramuscular midazolam versus intravenous lorazepam in the prehospital treatment of status epilepticus by paramedics.</article-title>
            <source>Epilepsia</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>52 Suppl 8</volume>
            <issue>Suppl 8</issue>
            <fpage>45</fpage>
            <page-range>45-7</page-range>
            <pub-id pub-id-type="pmid">21967361</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chamberlain</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Kapur</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shinnar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Elm</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Holsti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Babcock</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barsan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Cloyd</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lowenstein</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bleck</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Conwit</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Meinzer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cock</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fountain</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Underwood</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Connor</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Silbergleit</surname>
                <given-names>R</given-names>
              </name>
              <collab>Neurological Emergencies Treatment Trials</collab>
              <collab>Pediatric Emergency Care Applied Research Network investigators</collab>
            </person-group>
            <article-title>Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial.</article-title>
            <source>Lancet</source>
            <year>2020</year>
            <month>Apr</month>
            <day>11</day>
            <volume>395</volume>
            <issue>10231</issue>
            <fpage>1217</fpage>
            <page-range>1217-1224</page-range>
            <pub-id pub-id-type="pmid">32203691</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rossetti</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Milligan</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Vulli&#x000e9;moz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Michaelides</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bertschi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>A randomized trial for the treatment of refractory status epilepticus.</article-title>
            <source>Neurocrit Care</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>4</fpage>
            <page-range>4-10</page-range>
            <pub-id pub-id-type="pmid">20878265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shorvon</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Super-refractory status epilepticus: an approach to therapy in this difficult clinical situation.</article-title>
            <source>Epilepsia</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>52 Suppl 8</volume>
            <fpage>53</fpage>
            <page-range>53-6</page-range>
            <pub-id pub-id-type="pmid">21967364</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Titulaer</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>McCracken</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gabilondo</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Armangu&#x000e9;</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Glaser</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Iizuka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Honig</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Benseler</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Kawachi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Martinez-Hernandez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Aguilar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gresa-Arribas</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ryan-Florance</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Torrents</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saiz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Balice-Gordon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study.</article-title>
            <source>Lancet Neurol</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>157</fpage>
            <page-range>157-65</page-range>
            <pub-id pub-id-type="pmid">23290630</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sakuma</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Awaya</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shiomi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yamanouchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Saito</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sugai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sasaki</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Acute encephalitis with refractory, repetitive partial seizures (AERRPS): a peculiar form of childhood encephalitis.</article-title>
            <source>Acta Neurol Scand</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>121</volume>
            <issue>4</issue>
            <fpage>251</fpage>
            <page-range>251-6</page-range>
            <pub-id pub-id-type="pmid">20028339</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laswell</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Chambers</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Whitsel</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Poudel</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>New-onset refractory status epilepticus in an adult with an atypical presentation of cat-scratch disease: successful treatment with high-dose corticosteroids.</article-title>
            <source>Pharmacotherapy</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>35</volume>
            <issue>6</issue>
            <fpage>e106</fpage>
            <page-range>e106-10</page-range>
            <pub-id pub-id-type="pmid">26044784</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kenney-Jung</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Vezzani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kahoud</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>LaFrance-Corey</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Muskardin</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Wirrell</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Howe</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Payne</surname>
                <given-names>ET</given-names>
              </name>
            </person-group>
            <article-title>Febrile infection-related epilepsy syndrome treated with anakinra.</article-title>
            <source>Ann Neurol</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>80</volume>
            <issue>6</issue>
            <fpage>939</fpage>
            <page-range>939-945</page-range>
            <pub-id pub-id-type="pmid">27770579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Westbrook</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Subramaniam</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Seagren</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Tarula</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Co</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Furstenberg-Knauff</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Payne</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Febrile Infection-Related Epilepsy Syndrome Treated Successfully With Anakinra in a 21-Year-Old Woman.</article-title>
            <source>WMJ</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>118</volume>
            <issue>3</issue>
            <fpage>135</fpage>
            <page-range>135-139</page-range>
            <pub-id pub-id-type="pmid">31682750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Hsia</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>HS</given-names>
              </name>
              <collab>CHEESE Study Group</collab>
            </person-group>
            <article-title>Therapeutic hypothermia for febrile infection-related epilepsy syndrome in two patients.</article-title>
            <source>Pediatr Neurol</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>47</volume>
            <issue>6</issue>
            <fpage>448</fpage>
            <page-range>448-50</page-range>
            <pub-id pub-id-type="pmid">23127267</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gofshteyn</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Wilfong</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Devinsky</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bluvstein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Charuta</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ciliberto</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Laux</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Marsh</surname>
                <given-names>ED</given-names>
              </name>
            </person-group>
            <article-title>Cannabidiol as a Potential Treatment for Febrile Infection-Related Epilepsy Syndrome (FIRES) in the Acute and Chronic Phases.</article-title>
            <source>J Child Neurol</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <page-range>35-40</page-range>
            <pub-id pub-id-type="pmid">27655472</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nabbout</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mazzuca</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hubert</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Peudennier</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Allaire</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Flurin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Aberastury</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Dulac</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of ketogenic diet in severe refractory status epilepticus initiating fever induced refractory epileptic encephalopathy in school age children (FIRES).</article-title>
            <source>Epilepsia</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>51</volume>
            <issue>10</issue>
            <fpage>2033</fpage>
            <page-range>2033-7</page-range>
            <pub-id pub-id-type="pmid">20813015</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khawaja</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>DeWolfe</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Szaflarski</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>New-onset refractory status epilepticus (NORSE)--The potential role for immunotherapy.</article-title>
            <source>Epilepsy Behav</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>47</volume>
            <fpage>17</fpage>
            <page-range>17-23</page-range>
            <pub-id pub-id-type="pmid">26010959</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gleichman</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dessain</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Balice-Gordon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies.</article-title>
            <source>Lancet Neurol</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>7</volume>
            <issue>12</issue>
            <fpage>1091</fpage>
            <page-range>1091-8</page-range>
            <pub-id pub-id-type="pmid">18851928</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Florance</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Szperka</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Campen</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Moss</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Peter</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gleichman</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Glaser</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents.</article-title>
            <source>Ann Neurol</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>66</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-8</page-range>
            <pub-id pub-id-type="pmid">19670433</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suleiman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brenner</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gill</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Brilot</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Antony</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dale</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>VGKC antibodies in pediatric encephalitis presenting with status epilepticus.</article-title>
            <source>Neurology</source>
            <year>2011</year>
            <month>Apr</month>
            <day>05</day>
            <volume>76</volume>
            <issue>14</issue>
            <fpage>1252</fpage>
            <page-range>1252-5</page-range>
            <pub-id pub-id-type="pmid">21464429</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Watson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rosemergy</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Abernethy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lanford</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Faciobrachial dystonic seizures in an Lgi1 VGKC-complex antibody-mediated encephalitis.</article-title>
            <source>Neurol Clin Pract</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>5</volume>
            <issue>6</issue>
            <fpage>536</fpage>
            <page-range>536-537</page-range>
            <pub-id pub-id-type="pmid">29595829</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Costello</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Kilbride</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Cryptogenic New Onset Refractory Status Epilepticus (NORSE) in adults-Infectious or not?</article-title>
            <source>J Neurol Sci</source>
            <year>2009</year>
            <month>Feb</month>
            <day>15</day>
            <volume>277</volume>
            <issue>1-2</issue>
            <fpage>26</fpage>
            <page-range>26-31</page-range>
            <pub-id pub-id-type="pmid">19013586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gall</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Jumma</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Mohanraj</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Five cases of new onset refractory status epilepticus (NORSE) syndrome: outcomes with early immunotherapy.</article-title>
            <source>Seizure</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>22</volume>
            <issue>3</issue>
            <fpage>217</fpage>
            <page-range>217-20</page-range>
            <pub-id pub-id-type="pmid">23333762</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129235.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Baalen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>H&#x000e4;usler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boor</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rohr</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sperner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kurlemann</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Panzer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stephani</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kluger</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Febrile infection-related epilepsy syndrome (FIRES): a nonencephalitic encephalopathy in childhood.</article-title>
            <source>Epilepsia</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>51</volume>
            <issue>7</issue>
            <fpage>1323</fpage>
            <page-range>1323-8</page-range>
            <pub-id pub-id-type="pmid">20345937</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
